Form 4: Tonix Pharmaceuticals Director, David L. Grange, Acquires Stock Options

Director David L. Grange acquired stock options in Tonix Pharmaceuticals Holding Corp. on May 23, 2024.

Summary

• On May 23, 2024, David L. Grange, a director of Tonix Pharmaceuticals Holding Corp., acquired 104,621 stock options.
• The options have an exercise price of $0.1745.
• The options vest on the earlier of the one-year anniversary of the grant date or the Issuer's 2025 Annual Meeting of Stockholders.
• The options expire on May 23, 2034.
• Following the transaction, Grange directly owns 104,621 derivative securities.

Sentiment

Score: 5

Explanation: This is a neutral event. It's a routine disclosure of stock option grants to a director.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be an indicator of management's confidence in the company's future prospects.

Stakeholder Impact

• The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with those of the shareholders.

Key Dates